Fruquintinib for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have colorectal cancer that has spread and cannot be removed with surgery.
- You are already receiving fruquintinib as part of early access or standard care in France.
- You agree to give blood samples for testing and allow your tumor tissue to be analyzed.
- You do not have another active cancer that needs treatment or affects your outlook.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
This trial tests a drug called fruquintinib for people with advanced colorectal cancer that has spread. It is for patients who have already tried several standard treatments and need a new option.
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.